Evidence map›Paper›PMID 33244163›Full record

ArticleActa pharmacologica Sinica2021

Pharmacokinetics, mass balance, and metabolism of [

Yuan-Dong Zheng, Hua Zhang, Yan Zhan, Yi-Cong Bian, Sheng Ma, Hai-Xian Gan, Xiao-Juan Lai, Yong-Qiang Liu, Yan-Chun Gong, Xue-Fang Liu and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Pharmacokinetics, mass balance, and metabolism of [Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  4. Pharmacokinetics, mass balance, and metabolism of [Cancer chemotherapy and pharmacology · 2025
    Article
  5. Influence of Genetic and Epigenetic Factors of P2YCardiovascular drugs and therapy · 2024
    Review
  6. Absorption, Distribution, Metabolism, and Excretion of [Molecules (Basel, Switzerland) · 2023
    Article
  7. Pharmacokinetics, Mass Balance and Metabolism of [European journal of drug metabolism and pharmacokinetics · 2023
    Article
  8. A mass balance study of [Frontiers in pharmacology · 2023
    Article
  9. Absorption, distribution, metabolism, and excretion of [Cancer chemotherapy and pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Yuan-Dong Zheng *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
Hua Zhang *Department of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, 215123, China.
Yan ZhanState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
Yi-Cong BianDepartment of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, 215123, China.
Sheng MaDepartment of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, 215123, China.
Hai-Xian GanState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
Xiao-Juan LaiJiangsu Vcare PharmaTech Co. Ltd., Nanjing, 211800, China.
Yong-Qiang LiuJiangsu Vcare PharmaTech Co. Ltd., Nanjing, 211800, China.
Yan-Chun GongJiangsu Vcare PharmaTech Co. Ltd., Nanjing, 211800, China.
Xue-Fang LiuJiangsu Vcare PharmaTech Co. Ltd., Nanjing, 211800, China.
Hong-Bin SunState Key Laboratory of Natural Medicines and Center of Drug Discovery, College of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Yong-Guo LiGuangzhou JOYO Pharma Ltd., Shanghai, 201203, China.
Da-Fang ZhongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. dfzhong@simm.ac.cn.
Li-Yan MiaoDepartment of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, 215123, China. miaolysuzhou@163.com.
Xing-Xing DiaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. xxdiao@simm.ac.cn.
University of Chinese Academy of Sciences · CNFirst Affiliated Hospital of Soochow University · CNSoochow University · CNChina Pharmaceutical University · CNChinese Academy of Sciences · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vicagrel, a novel irreversible P2Y

Indexed as

Administration, OralAdultClopidogrelHumansMalePhenylacetatesPurinergic P2Y Receptor AntagonistsThiophenesClopidogrelmethyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetatePhenylacetatesPurinergic P2Y Receptor AntagonistsThiophenes[14C]vicagrelmass balanceP2Y12 receptor inhibitorvicagrelvicagrel metabolismvicagrel pharmacokinetics

Identifiers

PMID33244163
PMCPMC8379165
OpenAlexW3108803386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.